What is the recommended dose of SEROQUEL (quetiapine) for treating substance-induced psychosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

SEROQUEL Dosing for Substance-Induced Psychosis

For substance-induced psychosis, start quetiapine at 12.5 mg twice daily and titrate cautiously to a maximum of 200 mg twice daily, monitoring closely for sedation and orthostatic hypotension. 1

Initial Dosing Strategy

  • Begin with 12.5 mg twice daily as the starting dose for quetiapine in psychotic presentations 1
  • This conservative approach minimizes side effects while establishing tolerability, particularly important given quetiapine's sedating properties 1
  • Monitor for transient orthostatic hypotension, which is a notable concern with quetiapine initiation 1

Dose Titration

  • Increase doses only at widely spaced intervals of 14-21 days after initial titration, and only if response has been inadequate 2
  • Titrate within the limits of sedation and emergence of side effects 2
  • Maximum dose is 200 mg twice daily (400 mg total daily) 1
  • Research supports that quetiapine can be effectively dosed twice daily rather than three times daily despite its 7-hour half-life 3

Clinical Context for Substance-Induced Psychosis

While the available guidelines primarily address first-episode psychosis and schizophrenia rather than substance-induced psychosis specifically, the dosing principles remain applicable with important caveats:

  • Use the lower end of the dosing range given that substance-induced psychosis may resolve with abstinence and supportive care
  • The sedating properties of quetiapine 1 may be beneficial for agitation but require careful monitoring in patients with active substance use
  • Rule out ongoing substance intoxication or withdrawal before attributing symptoms solely to psychosis and initiating antipsychotic treatment 2

Key Safety Considerations

  • Quetiapine is more sedating than other atypical antipsychotics like risperidone or olanzapine 1
  • Watch for orthostatic hypotension, particularly during dose initiation and escalation 1
  • Quetiapine produces minimal extrapyramidal symptoms and does not cause sustained prolactin elevation 3, 4
  • Avoid exceeding maximum recommended doses, as this increases side effects without improving efficacy 2

Alternative Considerations

If quetiapine is poorly tolerated or ineffective, consider switching to:

  • Risperidone 2 mg/day (maximum 4 mg/day in first-episode psychosis) 2
  • Olanzapine 7.5-10 mg/day (maximum 20 mg/day) 2

These alternatives have more robust evidence for acute psychosis but may have different side effect profiles that are less desirable in substance-induced presentations.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Psychotic Features with Hallucinations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.